- Investopedia•4 days ago
Small- and mid-cap biotechs are attracting healthy buying interest and setting off bullish divergences that support higher prices into year-end.
- Zacks•5 days ago
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
- GlobeNewswire•8 days agoSupernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults
ROCKVILLE, Md., Aug. 19, 2016-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||20.51 x 200|
|Ask||23.00 x 100|
|Day's Range||21.38 - 22.11|
|52wk Range||9.51 - 24.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||45.04|
|Avg Vol (3m)||527,179|
|Dividend & Yield||N/A (N/A)|